Chelsea Counsel Company’s Biogen BIIB Stock Holding History

Chelsea Counsel Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,500	Closed	-$425K	–	83
2016 Q4	$425K	Hold	1,500	–	–	0.22%	68
2016 Q3	$470K	Sell	1,500 -2,200	-59%	-$652K	0.24%	62
2016 Q2	$895K	Hold	3,700	–	–	0.4%	50
2016 Q1	$963K	Hold	3,700	–	–	0.31%	56
2015 Q4	$1.13M	Sell	3,700 -1,100	-23%	-$316K	0.34%	54
2015 Q3	$1.4M	Buy	4,800 +2,500	+109%	+$826K	0.33%	54
2015 Q2	$929K	Buy	2,300 +300	+15%	+$120K	0.21%	62
2015 Q1	$844K	Sell	2,000 -23	-1%	-$9.06K	0.18%	63
2014 Q4	$687K	Buy	2,023 +1,000	+98%	+$324K	0.14%	68
2014 Q3	$338K	Sell	1,023 -600	-37%	-$198K	0.07%	98
2014 Q2	$512K	Buy	+1,623	New	+$488K	0.1%	80
2014 Q1	–	Sell	-1,023	Closed	-$286K	–	124
2013 Q4	$286K	Hold	1,023	–	–	0.07%	87
2013 Q3	$246K	Sell	1,023 -800	-44%	-$179K	0.05%	100
2013 Q2	$392K	Buy	+1,823	New	+$390K	0.1%	70

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Chelsea Counsel Company's BIIB Position: Q1 2017 in Review

Chelsea Counsel Company sold out of Biogen (BIIB) in Q1 2017, closing a stake of 1,500 shares — an estimated $425K sold.

Chelsea Counsel Company first reported a position in BIIB in Q2 2013 and held it in 14 quarters. The position peaked at $1.4M in Q3 2015. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

Chelsea Counsel Company reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
Chelsea Counsel Company sold 1,500 Biogen shares in Q1 2017, an estimated $425K.
Chelsea Counsel Company first reported a position in Biogen in Q2 2013 and held it in 14 quarters.
Chelsea Counsel Company's Biogen position peaked at $1.4M in Q3 2015.
1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Chelsea Counsel Company's 13F filing for Q1 2017, filed 20 Apr 2017.